Cefsulodin Chemische Eigenschaften,Einsatz,Produktion Methoden
R-Sätze Betriebsanweisung:
R20/21/22:Gesundheitsschädlich beim Einatmen,Verschlucken und Berührung mit der Haut.
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
S-Sätze Betriebsanweisung:
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
Beschreibung
Cefsulodin is a semi-synthetic, third-generation cephalosporin antibiotic with a narrow spectrum of activity. It was first synthesized and patented by the Takeda Pharmaceutical Company in 1977. Cefsulodin has activity against Pseudomonas aeruginosa and Staphylococcus aureus but little activity against other bacteria. It is eliminated renally and has a serum half-life similar to ceftazidime and cefoperazone. Cefsulodin appears to be well tolerated and relatively free of any significant toxicity except for nausea and vomiting, which appear to be related to the infusion rate.
Verwenden
Cefsulodin is a third generation cephalosporin antibiotic that has very specific activity against Pseudomonas aeruginosa. Cefuslodin is used in CIN (cefsulodin-Irgasan-novobiocin) agar to select for microorganisms such as E. coli. Cefsulodin is a substrate for rat Oatp1a4. It has been used to study multidrug resistance-associated protein 4 in efflux transport of prostaglandin E2 across the mouse blood-brain barrier. Cefsulodin is used to study the effect of expression, binding, and inhibition of PBP1 and other penicillin-binding proteins (PBPs) on bacterial cell wall mucopeptide synthesis.
Definition
ChEBI: Cefsulodin is a pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic. It has a role as an antibacterial drug. It is a cephalosporin, a primary carboxamide and an organosulfonic acid.
Antimicrobial activity
A semisynthetic parenteral cephalosporin supplied as the
sodium salt. Activity against Ps. aeruginosa contrasts strikingly
with poor activity against many other organisms.
Anaerobic Gram-negative rods, Gram-positive rods and cocci
are all resistant. It is stable to many β-lactamases, including the
Ps. aeruginosa chromosomal enzyme, and is a poor substrate
for the enzymes of Enterobacter spp. and Morg. morganii. It is
slowly hydrolyzed by TEM β-lactamases and more rapidly by
the enzymes of some carbenicillin-resistant strains of Ps. aeruginosa,
with which distinct inoculum effects may be seen.
A 500 mg intravenous bolus dose achieves a plasma concentration
of c. 70 mg/L at the end of the injection; the corresponding
intramuscular dose achieves a peak concentration of
around 15 mg/L. The plasma half-life is 1.5 h. About 15–30%
is protein bound.
There is some metabolism of the drug, but the main route
of excretion is via the kidneys, most appearing in the urine
in the first 6 h. The plasma half-life is linearly related to creatinine
clearance, rising to a mean of 10–13 h in patients
where clearance was <10 mL/min, falling to around 2 h on
hemodialysis.
It is well tolerated, apart from nausea and vomiting in some
subjects. It has been used in severe pseudomonas infections,
usually in combination with an aminoglycoside, but treatment
has been complicated on a number of occasions by the emergence
of resistance or superinfection.
It is available in Japan.
Cefsulodin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
